MARKET

IMPL

IMPL

IMPEL NEUROPHARMA INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.03
-0.42
-3.12%
After Hours: 13.15 +0.12 +0.92% 19:24 09/24 EDT
OPEN
13.03
PREV CLOSE
13.45
HIGH
13.70
LOW
12.92
VOLUME
489.20K
TURNOVER
--
52 WEEK HIGH
34.75
52 WEEK LOW
6.90
MARKET CAP
292.80M
P/E (TTM)
-5.4619
1D
5D
1M
3M
1Y
5Y
Top Stocks Targeting the Underserved $5.7B Parkinson's Opportunity (PRTA, ITCI, ATRX, QURE, GMAB, IMPL, AMRX)
WallStreetPR · 3d ago
Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Maintains Outperform Rating
MT Newswires · 09/15 10:23
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86.
Benzinga · 09/10 19:07
ATER, CEI and RLX among mid-day movers
Gainers: IVERIC (NASDAQ:ISEE) +62%. Echo (NASDAQ:ECHO) +53%. Endo International plc (NASDAQ:ENDP) +35%. Affirm (NASDAQ:AFRM) +32%. Elite Education (NASDAQ:EEIQ) +30%. SigmaTron (NASDAQ:SGMA) +25%. Onion Global (NYSE:OG) +21%. Farmmi (NASDAQ:FAMI) +20%. Ate...
Seekingalpha · 09/10 16:36
Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge
Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84.
Benzinga · 09/10 16:31
41 Stocks Moving In Friday's Mid-Day Session
Gainers
Benzinga · 09/10 16:23
IVERIC bio, Endo leads healthcare gainers; Apellis Pharmaceuticals, Mersana Therapeutics among major losers
Gainers: IVERIC bio (NASDAQ:ISEE) +56%, Endo (NASDAQ:ENDP) +46%, NGM Biopharmaceuticals (NASDAQ:NGM) +16%, Arbutus Biopharma (NASDAQ:ABUS) +15%, CareMax (NASDAQ:CMAX) +11%. Losers: Apellis Pharmaceuticals (NASDAQ:APLS) -50%, Mersana Therapeutics (NASDAQ:MR...
Seekingalpha · 09/10 15:09
Impel NeuroPharma To Raise $45M Via Equity Offering
Benzinga · 09/10 11:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMPL. Analyze the recent business situations of IMPEL NEUROPHARMA INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMPL stock price target is 48.00 with a high estimate of 55.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 16.92M
% Owned: 75.29%
Shares Outstanding: 22.47M
TypeInstitutionsShares
Increased
0
0
New
33
16.92M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Adrian Adams
Co-Founder/Chief Scientific Officer
John Hoekman
Chief Financial Officer/Primary Contact
John Leaman
Senior Vice President
Lynn Gold
Senior Vice President
Scott Youmans
No Data
About IMPL
Impel NeuroPharma, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS). The Company offers Precision Olfactory Delivery (POD), which is a upper nasal delivery technology with well-established therapeutics or other therapeutics where vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within its target diseases. The Company’s product candidates TRUDHESATM (INP104) is developed for providing acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder (ASD). Its pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson’s Disease.

Webull offers kinds of Impel Neuropharma Inc stock information, including NASDAQ:IMPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMPL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMPL stock methods without spending real money on the virtual paper trading platform.